CY1114912T1 - Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου - Google Patents

Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου

Info

Publication number
CY1114912T1
CY1114912T1 CY20141100076T CY141100076T CY1114912T1 CY 1114912 T1 CY1114912 T1 CY 1114912T1 CY 20141100076 T CY20141100076 T CY 20141100076T CY 141100076 T CY141100076 T CY 141100076T CY 1114912 T1 CY1114912 T1 CY 1114912T1
Authority
CY
Cyprus
Prior art keywords
vaccine
methods
breast cancer
inducing
patient
Prior art date
Application number
CY20141100076T
Other languages
Greek (el)
English (en)
Inventor
George E Peoples
Ponniah Sathibalan
Original Assignee
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. filed Critical The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
Publication of CY1114912T1 publication Critical patent/CY1114912T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20141100076T 2007-06-01 2014-01-30 Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου CY1114912T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94152407P 2007-06-01 2007-06-01
EP08745615.8A EP2162149B1 (en) 2007-06-01 2008-04-11 Vaccine for the prevention of breast cancer relapse

Publications (1)

Publication Number Publication Date
CY1114912T1 true CY1114912T1 (el) 2017-01-25

Family

ID=40094045

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100076T CY1114912T1 (el) 2007-06-01 2014-01-30 Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου

Country Status (16)

Country Link
US (6) US8222214B2 (https=)
EP (2) EP2722336A1 (https=)
JP (6) JP5635399B2 (https=)
KR (5) KR101572474B1 (https=)
CN (2) CN105816867A (https=)
AU (1) AU2008260399C1 (https=)
CA (1) CA2687368C (https=)
CY (1) CY1114912T1 (https=)
DK (1) DK2162149T3 (https=)
ES (1) ES2445399T3 (https=)
HR (1) HRP20140102T1 (https=)
MX (1) MX2009012858A (https=)
PL (1) PL2162149T3 (https=)
PT (1) PT2162149E (https=)
SI (1) SI2162149T1 (https=)
WO (1) WO2008150577A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
HRP20140102T1 (hr) * 2007-06-01 2014-03-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cjepivo za prevenciju relapsa raka dojke
KR20170097234A (ko) 2008-12-10 2017-08-25 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 유방암 재발 예방용 백신
CN104271591B (zh) 2012-02-17 2017-09-26 梅约医学教育与研究基金会 用于生成能够识别表达HER2/neu多肽的癌细胞的CD8+T细胞的方法和材料
WO2013169538A1 (en) 2012-05-08 2013-11-14 Albert Einstein College Of Medicine Of Yeshiva University Nanoparticle delivery vehicle for s-nitroso-n-acetyl cysteine and uses thereof
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
AR094403A1 (es) * 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
CA2840997A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
CN103961700A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
WO2015066020A1 (en) * 2013-10-28 2015-05-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of monitoring immune responses
US10434152B2 (en) * 2014-02-20 2019-10-08 Wayne State University HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas
WO2017132562A1 (en) 2016-01-29 2017-08-03 Heyue Zhou Antigen binding proteins that bind pd-l1
EP3463438B1 (en) 2016-05-31 2022-04-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
US11564987B2 (en) 2018-10-21 2023-01-31 Slsg Limited Llc Combination immunotherapy for treatment of triple-negative breast cancer
US20240183856A1 (en) 2021-05-04 2024-06-06 Aston Sci. Inc. Her2 vaccine composition
KR20230017640A (ko) 2021-07-28 2023-02-06 주식회사 애스톤사이언스 Her2 백신 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
DE69031120T2 (de) * 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO1996018409A1 (en) * 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US20030022820A1 (en) * 1995-12-14 2003-01-30 Linda A. Sherman In vivo activation of tumor-specific cytotoxic t cells
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1246597B1 (en) * 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
AU7743100A (en) 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20030224036A1 (en) * 1999-12-13 2003-12-04 Fikes John D Hla class I a2 tumor associated antigen peptides and vaccine compositions
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
WO2003004609A2 (en) * 2001-07-03 2003-01-16 Lexicon Genetics Incorporated Novel human kielin-like proteins and polynucleotides encoding the same
WO2003005952A2 (en) * 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US8802618B2 (en) 2002-03-08 2014-08-12 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
KR100555211B1 (ko) * 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신
EP1553966B1 (en) * 2002-10-03 2012-08-01 Wyeth Holdings Corporation Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof
WO2004069866A1 (en) * 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
WO2005046571A2 (en) * 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005014634A1 (en) 2003-08-12 2005-02-17 Agt Biosciences Limited A gene and uses therefor
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
US20060275777A1 (en) * 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
HRP20140102T1 (hr) * 2007-06-01 2014-03-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cjepivo za prevenciju relapsa raka dojke

Also Published As

Publication number Publication date
KR102079921B1 (ko) 2020-02-21
KR101572474B1 (ko) 2015-11-30
KR20100027187A (ko) 2010-03-10
US9370560B2 (en) 2016-06-21
US8796220B2 (en) 2014-08-05
EP2722336A1 (en) 2014-04-23
SI2162149T1 (sl) 2014-04-30
JP6097724B2 (ja) 2017-03-15
JP2014237653A (ja) 2014-12-18
DK2162149T3 (da) 2014-02-10
AU2008260399A1 (en) 2008-12-11
HRP20140102T1 (hr) 2014-03-28
PL2162149T3 (pl) 2014-04-30
MX2009012858A (es) 2010-02-03
KR20150106870A (ko) 2015-09-22
US20100209443A1 (en) 2010-08-19
CA2687368A1 (en) 2008-12-11
JP2010529026A (ja) 2010-08-26
JP2022095926A (ja) 2022-06-28
JP2018199691A (ja) 2018-12-20
KR20200019776A (ko) 2020-02-24
EP2162149A4 (en) 2012-07-25
KR101863534B1 (ko) 2018-06-04
CA2687368C (en) 2018-10-30
JP2021001218A (ja) 2021-01-07
CN101678093A (zh) 2010-03-24
US8222214B2 (en) 2012-07-17
AU2008260399C1 (en) 2014-07-17
ES2445399T3 (es) 2014-03-03
EP2162149A1 (en) 2010-03-17
US20190060429A1 (en) 2019-02-28
JP2017071607A (ja) 2017-04-13
US20150182609A1 (en) 2015-07-02
EP2162149B1 (en) 2013-11-06
JP5635399B2 (ja) 2014-12-03
KR20180061412A (ko) 2018-06-07
WO2008150577A1 (en) 2008-12-11
CN105816867A (zh) 2016-08-03
US20130189290A1 (en) 2013-07-25
KR20210097209A (ko) 2021-08-06
PT2162149E (pt) 2014-02-12
JP7072467B2 (ja) 2022-05-20
US20220347281A1 (en) 2022-11-03
KR102283639B1 (ko) 2021-08-02
AU2008260399B2 (en) 2014-01-16
AU2008260399A8 (en) 2010-01-07
US20220241389A1 (en) 2022-08-04
US10842856B2 (en) 2020-11-24

Similar Documents

Publication Publication Date Title
CY1114912T1 (el) Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου
Abu Eid et al. Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition
Zitvogel et al. Immunological off-target effects of imatinib
Vacchelli et al. Trial watch: Peptide vaccines in cancer therapy
MX2021015354A (es) Composiciones y metodos para administracion subcutanea de inmunoterapia de cancer.
CY1123526T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
Wachowska et al. 5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy
MX2010001086A (es) Nueva inmunoterapia contra tumores neuronales y cerebrales.
DK2102331T3 (da) Anti-tumorvaccine afledt af normale kemisk modificerede CD4 -celler
CY1110013T1 (el) Συνδυασμοι για θεραπεια πολλαπλου μυελωματος
CY1124950T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
BR112016025035A2 (pt) imunoterapia contra diversos tumores hematológicos, como a leucemia mieloide aguda (aml)
MX2010001088A (es) Composicion de peptidos asociados a tumor y vacunas relacionadas contra el cancer.
EP2228072A4 (en) CANCER VACCINE COMPOSITION
MX2015010880A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
NZ601677A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
BRPI0510430A (pt) composições e métodos para vacinação mucosal
BRPI0408774A (pt) vacinas de dna contra crescimento tumoral e seus usos
MX2010002002A (es) Peptido foxm1 y agente medicinal que lo contiene.
CY1124812T1 (el) Μεθοδος ανοσοενισχυτικης θεραπευτικης αντιμετωπισης του καρκινου
Zhang et al. Procyanidin, a kind of biological flavonoid, induces protective anti-tumor immunity and protects mice from lethal B16F10 challenge
BRPI0820960B8 (pt) composição, composição farmacêutica, e uso da composição
CY1118486T1 (el) Λαπατινιμπη για τη θεραπεια του καρκινου